PREIMPLANTATION GENETIC DIAGNOSIS MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America dominates the preimplantation genetic diagnosis market with an estimated market share of 41.2% in 2024. The U.S. accounts for the largest share and is home to several leading players in this field. Advanced medical technologies, high healthcare expenditure by both public and private players, and favorable medical reimbursement policies is expected to drive the market growth in the U.S. Growing preference for IVF treatments together with awareness regarding genetic disorders has significantly boosted demand.

Asia Pacific region, especially China and India, is witnessing the fastest growth. Rapid economic development and rising affluence over the past decade has improved access to advanced healthcare facilities in the major Asian economies. Growing medical tourism sector catering to global patients has also provided a fillip. While regulations regarding genetic screening are still evolving, private clinics in major cities successfully promote selective sex services to attract customers. This has promoted the use of PGD as a value-added service.